Forte Biosciences, Inc. (NASDAQ:FBRX) CFO Acquires 22,514 Shares

Forte Biosciences, Inc. (NASDAQ:FBRX) CFO Antony A. Riley bought 22,514 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The shares were purchased at an average price of $5.55 per share, for a total transaction of $124,952.70. Following the completion of the purchase, the chief financial officer now directly owns 30,776 shares of the company’s stock, valued at approximately $170,806.80. This trade represents a 272.50 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Forte Biosciences Price Performance

Shares of NASDAQ FBRX traded up $0.36 during midday trading on Friday, hitting $16.00. 395,225 shares of the company’s stock were exchanged, compared to its average volume of 142,173. The firm’s fifty day simple moving average is $5.73 and its 200-day simple moving average is $2.58. The company has a market cap of $23.36 million, a PE ratio of -0.88 and a beta of 0.04. Forte Biosciences, Inc. has a twelve month low of $4.11 and a twelve month high of $21.25.

Analysts Set New Price Targets

Separately, Chardan Capital increased their price objective on shares of Forte Biosciences from $3.00 to $64.00 and gave the company a “buy” rating in a research report on Friday, November 15th.

About Forte Biosciences

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.